Dapagliflozin propanediol monohydrate
Alimentary tract & metabolism
EU DMF readiness
US DMF readiness
Dapagliflozin belongs to anti-diabetic agents class.
It is indicated for the treatment of type 2 diabetes in adults aged 18 years and older with type 2 diabetes mellitus to improve glycemic control as mono-therapy and as add-on combination, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
It is formulated as film-coated tablets and tablets for oral administration and intravenous administration.
Mechanism of action:
Dapagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor. The renal SGLT system plays a major role in overall glucose balance in the body. Dapagliflozin by an insulin independent mechanism leads to the excretion of excess glucose and associated calories in the urine, thereby lowering blood glucose levels.
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.